Bioxytran, Inc. (OTCMKTS:BIXT) Short Interest Update

Bioxytran, Inc. (OTCMKTS:BIXTGet Free Report) was the target of a significant growth in short interest in the month of August. As of August 31st, there was short interest totalling 70,700 shares, a growth of 644.2% from the August 15th total of 9,500 shares. Based on an average trading volume of 249,000 shares, the days-to-cover ratio is currently 0.3 days.

Bioxytran Stock Up 18.8 %

BIXT stock opened at $0.19 on Thursday. The business’s 50-day moving average is $0.17 and its two-hundred day moving average is $0.31. Bioxytran has a 1 year low of $0.12 and a 1 year high of $1.15.

Bioxytran (OTCMKTS:BIXTGet Free Report) last posted its quarterly earnings results on Monday, July 31st. The company reported ($0.01) EPS for the quarter. On average, equities research analysts predict that Bioxytran will post -0.02 EPS for the current fiscal year.

Bioxytran Company Profile

(Get Free Report)

Bioxytran, Inc, a clinical stage pharmaceutical company, focuses on the development, manufacture, and commercialization of therapeutic drugs to address hypoxia in humans. The company's lead drug candidate is BXT-25, an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer for use in the treatment of hypoxic conditions in the brain resulting from stroke, and hypoxic conditions in wounds to prevent necrosis and to promote healing.

Featured Stories

Receive News & Ratings for Bioxytran Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioxytran and related companies with's FREE daily email newsletter.